Pharmacogenetics in irritable bowel syndrome

Acosta A1, Camilleri M. Expert Opin Drug Metab Toxicol. 2015 Aug;11(8):1187-91. doi: 10.1517/17425255.2015.1048223. Epub 2015 Jun 30.
Author information

1Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic , Charlton 8-110, 200 First St. S.W, chester, MN 55905, Rochester, MN , USA +1 507 266 2305 ; camilleri.michael@mayo.edu.


Irritable bowel syndrome (IBS) is a chronic disease characterized by complex interactions between genetic predisposition and the environment. Current treatments for IBS are characterized by a highly variable response. Gene variations may result from insertions or deletions, gene rearrangements, splice variants or copy number variants, or, more commonly, from substitutions in the DNA of one (single nucleotide polymorphism [SNPs]) or more than one nucleotide. The objective of this editorial is to review the potential importance of pharmacogenetics in the treatment of IBS based on current evidence.

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.